32246-20-1

Usage

Uses

Used in Pharmaceutical Synthesis:
5-Bromo-2,4-dimethoxybenzoic acid 97 is used as an intermediate in the synthesis of pharmaceuticals for its ability to participate in a range of chemical reactions due to its bromine and methoxy functional groups. This makes it a valuable component in the development of new drugs and medicinal compounds.
Used in Organic Chemistry Research:
In the field of organic chemistry, 5-Bromo-2,4-dimethoxybenzoic acid 97 is used as a research compound to explore its reactivity and potential applications in the creation of new organic compounds. Its unique structure allows researchers to investigate its properties and behavior in different chemical environments.
Used in Chemical Reactions:
5-Bromo-2,4-dimethoxybenzoic acid 97 is utilized as a reactant in various chemical processes, taking advantage of its bromine and methoxy groups to form new compounds or modify existing ones. Its versatility in reactions makes it a useful tool in the synthesis of a wide array of organic products.
Used in Material Science:
In material science, 5-Bromo-2,4-dimethoxybenzoic acid 97 may be employed to develop new materials with specific properties, such as improved stability or reactivity. Its incorporation into polymers or other materials can enhance their performance in various applications.
Used in Analytical Chemistry:
5-Bromo-2,4-dimethoxybenzoic acid 97 can be used as a standard or reference compound in analytical chemistry for the calibration of instruments or the development of new analytical methods. Its purity and well-defined structure make it suitable for these purposes.

InChI:InChI=1/C9H9BrO4/c1-13-7-4-8(14-2)6(10)3-5(7)9(11)12/h3-4H,1-2H3,(H,11,12)

Upstream product

• 32246-73-4 1,7-Bis(2,4-dimethoxy-5-bromphenyl)-heptan-1,7-dion 
• 91-52-1 2,4 dimethoxybenzoic acid 
• 7726-95-6 bromine 
• 64-19-7 acetic acid 
• 82040-68-4 (E)-5-bromo-2,4-dimethoxy-β-nitrostyrene 
• 67-64-1 acetone 
• 130333-46-9 5-bromo-2, 4-dimethoxybenzaldehyde 
• 7487-88-9 magnesium sulfate 
• 89-86-1 4-hydroxysalicylic acid 
• 6615-24-3 2-hydroxy-4-methoxy-5-nitrobenzaldehyde 
• 57543-36-9 5-bromo-2-hydroxy-4-methoxybenzaldehyde 
• 17715-69-4 1-Bromo-2,4-dimethoxybenzene 
• 124-38-9 carbon dioxide 
• 24988-36-1 4,6-dibromo-1,3-dimethoxybenzene 

Downstream Products

• 39503-51-0 2,4-Dimethoxy-5-bromobenzoic acid methyl ester 
• 24988-36-1 4,6-dibromo-1,3-dimethoxybenzene 
• 1235306-70-3 2-(5'-bromo-2',4'-dimethoxyphenyl)-N-acetylindole 
• 1215952-03-6 5-bromo-2,4-dimethoxybenzonitrile 
• 82040-68-4 (E)-5-bromo-2,4-dimethoxy-β-nitrostyrene 
• 1159205-71-6 (E)-diethyl (3-(5-bromo-2,4-dimethoxyphenyl)allyl)malonate 
• 1159205-72-7 C₁₈H₂₃BrO₆ 
• 1171823-91-8 ethyl 2-(5-bromo-2,4-dimethoxybenzoyl)-3-(dimethylamino)acrylate 
• 213764-46-6 (+/-) N-(1,2-Dimethyl-1,2,3,4-tetrahydroisoquinolin-5-yl)-5-bromo-2,4-dimethoxybenzamide, hydrochloride 
• 99446-05-6 6-chloro-8-(5-bromo-2,4-dimethoxy-phenyl)-purine 
• 96901-84-7 5-bromo-2,4-dimethoxy-N-(1-benzyl-4-piperidinyl)benzamide 
• 130890-81-2 5-bromo-4-methoxy-N-(1-benzyl-4-piperidinyl)salicylamide 

Relevant academic research and scientific papers

Preparation method of elviravir

The invention provides a preparation method of elviravir, and belongs to the technical field of medicine preparation. According to the method, 2, 4-dimethoxybenzoic acid is used as a raw material and is sequentially subjected to a bromination reaction, an

Peroxidative bromination and oxygenation of organic compounds: Synthesis, X-ray crystal structure and catalytic implications of mononuclear and binuclear oxovanadium(V) complexes containing Schiffbase ligands

Treatment of of (R,R)-N,N-salicylidene cyclohexane 1,2-diamine(H 2L1) in methanol with aqueous NH4VO3 solution in perchloric acid medium affords the mononuclear oxovanadium(V) complex [VOL1(MeOH)]·ClO4 (1) as deep blue solid while the treatment of same solution of (R,R)-N,N-salicylidene cyclohexane 1,2-diamine(H2L1) with aqueous solution of VOSO 4 leads to the formation of di-(μ-oxo) bridged vanadium(V) complex [VO2L2]2 (2) as green solid where HL 2 = (R,R)-N-salicylidene cyclohexane 1,2-diamine. The ligand HL 2 is generated in situ by the hydrolysis of one of the imine bonds of HL1 ligand during the course of formation of complex [VO 2L2]2 (2). Both the compounds have been characterized by single crystal X-ray diffraction as well as spectroscopic methods. Compounds 1 and 2 are to act as catalyst for the catalytic bromide oxidation and C-H bond oxidation in presence of hydrogen peroxide. The representative substrates 2,4-dimethoxy benzoic acid and para-hydroxy benzoic acids are brominated in presence of H2O2 and KBr in acid medium using the above compounds as catalyst. The complexes are also used as catalyst for C-H bond activation of the representative hydrocarbons toluene, ethylbenzene and cyclohexane where hydrogen peroxide acts as terminal oxidant. The yield percentage and turnover number are also quite good for the above catalytic reaction. The oxidized products of hydrocarbons have been characterized by GC Analysis while the brominated products have been characterized by 1H NMR spectroscopic studies.

TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR

5-[4-(2-Methylphenyl)-3-hydroxy-4H-1,2,4-triazol-5-yl]-2,4-dihydroxy-N-methyl-N-butylbenzamide is an HSP90 inhibitor and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

PROCESS FOR PRODUCTION OF 4-OXOQUINOLINE COMPOUND

The present invention provides a compound useful as a synthetic intermediate for an anti-HIV agent having an integrase inhibitory activity, a production method thereof, and a production method of an anti-HIV agent using the synthetic intermediate. Specifi

Total synthesis of psoralidin, an anticancer natural product

A base-catalyzed condensation of phenyl acetate with acid chloride, followed by intramolecular cyclization and microwave-assisted cross-metathesis reaction, leads to the first total synthesis of psoralidin, a natural product with a broad range of biological activities, in a highly convergent and regioselective manner.

METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND

The present invention provides a compound useful as a synthetic intermediate for an anti-HIV agent having an integrase inhibitory activity, and a production method thereof, and a production method of an anti-HIV agent using the synthetic intermediate. Spe

TRIAZOLE DERIVATIVES

The invention relates to novel triazole derivatives of formula (I) wherein R1 - R6 and Y have the designations cited in patent claim 1. Said derivatives are HSP90 inhibitors, and can be used to produce a medicament for treating diseases wherefore the inhibition, regulation and/or modulation of HSP90 plays an important role.

Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity

Compounds of formula (I) and pharmaceutically acceptable salts and solvates: where R1is hydrogen, C1-6alkyl (optionally substituted by hydroxy or C1-4alkoxy), phenyl-C1-4alkyl-, C1-6alkenyl, C1-6

Substituted isoquinoline derivatives and their use as anticonvulsivants

This invention relates to novel substituted isoquinoline derivatives and their use as anticonvulsants.

Anti-convulsant isoquinolyl-benzamide derivatives

Compounds of formula (I) and pharmaceutically acceptable salts thereof, where R1is hydrogen, C1-6alkyl (optionally substituted by hydroxy or C1-4alkoxy), C1-6alkenyl, C1-6alkynyl, C1-6alkylCO—, formyl, CF3CO— or C1-6alkylSO2—; R2is hydrogen or up to three substituents selected from halogen, NO2, CN, N3, CF3O—, CF3S—, CF3CO—, trifluoromethyldiazirinyl, C 1-6?alkyl, C1-6alkenyl, C1-6alkynyl, C1-6perfluoroalkyl, C3-6cycloalkyl, C3-6cycloalkyl-C1-4alkyl-, C1-6alkylO—, C1-6alkylCO—, C3-6cycloalkylO—, C3-6cycloalkylCO—, C3-6cycloalkyl-C1-4alkylO—, C3-6cycloalkyl-C1-4alkylCO—, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C1-4alkyl-, C1-6alkylS—, C1-6alkylSO2—, (C1-4alkyl)2NSO2—, (C1-4alkyl)NHSO2—, (C1-4alkyl)2NCO—, (C1-4alkyl)NHCO— or CONH2; or —NR5R6where R5is hydrogen or C1-4alkyl, and R6is hydrogen, C1-4alkyl, formyl, —CO2C1-4alkyl or —COC1-4alkyl; or two R2groups together form a carbocyclic ring that is saturated or unsaturated and unsubstituted or substituted by —OH or ═O; and the two R3groups and the two R4groups are each independently hydrogen or C1-6alkyl or the two R3groups and/or the two R4groups together form a C3-6spiroalkyl group provided that at least one R3and R4group is not hydrogen, are useful in the treatment and prophylaxis of epilepsy and other disorders.